Related Experiment Videos
Pharmacologic strategies for augmenting cognitive performance in schizophrenia
J I Friedman1, H Temporini, K L Davis
1Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA.
Biological Psychiatry
|January 23, 1999
Summary
Schizophrenia cognitive deficits, impacting learning and memory, may improve with D1 dopamine, norepinephrine, and cholinergic system drugs. These treatments target prefrontal cortex (PFC) pathways affected in schizophrenia.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Cognitive symptoms significantly impact schizophrenia outcomes.
- Prefrontal cortex (PFC) functions like working memory are impaired.
- D1 dopamine, norepinephrine, and cholinergic systems are implicated.
Purpose of the Study:
- To explore potential pharmacological treatments for cognitive deficits in schizophrenia.
- To identify neurotransmitter systems and receptor targets for cognitive enhancement.
Main Methods:
- Review of existing literature on neurobiology of schizophrenia cognition.
- Analysis of dopamine, norepinephrine, and acetylcholine roles in PFC function.
- Examination of drug mechanisms targeting relevant receptors.
Main Results:
- Decreased PFC D1 receptors in schizophrenia suggest D1 agonists or atypical neuroleptics may help.
- Reduced cortical norepinephrine (NE) and efficacy of alpha-2 adrenergic agonists in models indicate their potential.
- Correlation of choline acetyl transferase with cognitive scores suggests cholinergic drugs (acetylcholinesterase inhibitors, M1/M4 agonists) could be beneficial.
Conclusions:
- D1 receptor agonists, alpha-2 adrenergic agonists, and cholinomimetics show promise for treating schizophrenia-related cognitive impairments.
- Targeting PFC neurotransmitter systems offers a viable strategy for cognitive remediation in schizophrenia.